Krystal Biotech is trading 4.8% up at $371.96 in pre-market, extending last week’s strength despite a lack of fresh company-specific headlines or catalysts.
- The stock closed at $354.86 on July 17, 2026, and the current move appears aligned with a modest risk-on tone in U.S. futures.
- There are no new earnings, FDA decisions, or major analyst calls linked to the price action.
- The gain reflects broader resilience within the biotech sector as market sentiment remains positive.